| 摘要 |
A new administration regimen giving an extended plasma concentration profile of a H+, K+-ATPase inhibitor. The extended plasma profile is received by two or more consecutive administrations of a unit dose of a H+, K+-ATPase with 0.5-4 hours interval or by a pharmaceutical composition with extended release, which may be administered once daily. |
